| Literature DB >> 33619368 |
Matteo C Da Vià1, Oliver Dietrich2, Marietta Truger3, Panagiota Arampatzi4, Johannes Duell1, Anke Heidemeier5, Xiang Zhou1, Sophia Danhof1, Sabrina Kraus1, Manik Chatterjee1, Manja Meggendorfer3, Sven Twardziok3, Maria-Elisabeth Goebeler1, Max S Topp1, Michael Hudecek1, Sabrina Prommersberger1, Kristen Hege6, Shari Kaiser6, Viktoria Fuhr7, Niels Weinhold8, Andreas Rosenwald7, Florian Erhard9, Claudia Haferlach3, Hermann Einsele1, K Martin Kortüm1, Antoine-Emmanuel Saliba2, Leo Rasche10,11.
Abstract
B cell maturation antigen (BCMA) is a target for various immunotherapies and a biomarker for tumor load in multiple myeloma (MM). We report a case of irreversible BCMA loss in a patient with MM who was enrolled in the KarMMa trial ( NCT03361748 ) and progressed after anti-BCMA CAR T cell therapy. We identified selection of a clone with homozygous deletion of TNFRSF17 (BCMA) as the underlying mechanism of immune escape. Furthermore, we found heterozygous TNFRSF17 loss or monosomy 16 in 37 out of 168 patients with MM, including 28 out of 33 patients with hyperhaploid MM who had not been previously treated with BCMA-targeting therapies, suggesting that heterozygous TNFRSF17 deletion at baseline could theoretically be a risk factor for BCMA loss after immunotherapy.Entities:
Mesh：
Substances：
Year: 2021 PMID： 33619368 DOI： 10.1038/s41591-021-01245-5
Source DB: PubMed Journal: Nat Med ISSN： 1078-8956 Impact factor: 53.440